Palatin Technologies, Inc. (PTN)
NYSEAMERICAN: PTN · Real-Time Price · USD
0.4901
-0.0928 (-15.92%)
At close: Apr 1, 2025, 4:00 PM
0.5153
+0.0252 (5.14%)
After-hours: Apr 1, 2025, 4:47 PM EST

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.

In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.

Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials.

Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Palatin Technologies, Inc.
Palatin Technologies logo
Country United States
Founded 1986
IPO Date Oct 28, 1993
Industry Biotechnology
Sector Healthcare
Employees 30
CEO Carl Spana

Contact Details

Address:
Cedar Brook Corporate Center, 4-B Cedar Brook Drive
Cranbury, New Jersey 08512
United States
Phone 609 495 2200
Website palatin.com

Stock Details

Ticker Symbol PTN
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000911216
CUSIP Number 696077403
ISIN Number US6960775020
Employer ID 95-4078884
SIC Code 2834

Key Executives

Name Position
Dr. Carl Spana Ph.D. Co-Founder, President, Chief Executive Officer and Director
Burns McClellan Vice President of Investor Relations
Stephen A. Slusher Esq. Chief Legal Officer
Dr. Michael B. Raizman M.D. Chief Medical Officer
James E. Hattersley B.A., M.S. Senior Vice President of Business Development
John Dodd Ph.D. Senior Vice President of Preclinical Development
Robert Jordan Senior Vice President of Program Operations

Latest SEC Filings

Date Type Title
Mar 31, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Mar 31, 2025 8-K Current Report
Mar 7, 2025 DRS [Cover] Draft Registration Statement
Feb 14, 2025 SCHEDULE 13G Filing
Feb 13, 2025 10-Q Quarterly Report
Feb 12, 2025 424B5 Filing
Feb 12, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report
Feb 10, 2025 424B5 Filing
Dec 16, 2024 8-K Current Report